← Back to Search
Drug Resistance By Evasion Of Antiangiogenic Targeting Of VEGF Signaling In Late-stage Pancreatic Islet Tumors.
O. Casanovas, D. Hicklin, G. Bergers, D. Hanahan
Published 2005 · Biology, Medicine
Download PDFAnalyze on Scholarcy
Function-blocking antibodies to VEGF receptors R1 and R2 were used to probe their roles in controlling angiogenesis in a mouse model of pancreatic islet carcinogenesis. Inhibition of VEGFR2 but not VEGFR1 markedly disrupted angiogenic switching, persistent angiogenesis, and initial tumor growth. In late-stage tumors, phenotypic resistance to VEGFR2 blockade emerged, as tumors regrew during treatment after an initial period of growth suppression. This resistance to VEGF blockade involves reactivation of tumor angiogenesis, independent of VEGF and associated with hypoxia-mediated induction of other proangiogenic factors, including members of the FGF family. These other proangiogenic signals are functionally implicated in the revascularization and regrowth of tumors in the evasion phase, as FGF blockade impairs progression in the face of VEGF inhibition.
This paper references
Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors.
N. Cheng (2003)
The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era.
K. Miller (2003)
Vascular reactions to histamine, histamine‐liberator and leukotaxine in the skin of guinea‐pigs
A. Miles (1952)
Beta-cell lines derived from transgenic mice expressing a hybrid insulin gene-oncogene.
S. Efrat (1988)
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
G. Bergers (2000)
Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis.
F. Pezzella (1997)
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis.
M. Inoue (2002)
CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer.
D. Daniel (2005)
Methods in laboratory investigation: A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor
A. Passaniti (1992)
A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer
J. Joyce (2005)
T-cell tolerance toward a transgenic beta-cell antigen and transcription of endogenous pancreatic genes in thymus.
C. Jolicoeur (1994)
Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis.
G. Christofori (1995)
Fibroblast growth factors are required for efficient tumor angiogenesis.
A. Compagni (2000)
The biology of VEGF and its receptors
N. Ferrara (2003)
Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis.
J. Joyce (2004)
Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice.
S. Hiratsuka (1998)
Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes
D. Hanahan (1985)
Antiangiogenic Therapy of Cerebral Melanoma Metastases Results in Sustained Tumor Progression via Vessel Co-Option
W. Leenders (2004)
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent.
K. D. de Visser (2005)
Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches
R. Kerbel (2004)
Transformation of the microvascular system during multistage tumorigenesis
E. Ryschich (2002)
Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences.
H. Broxterman (2003)
A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor.
A. Passaniti (1992)
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1
A. Luttun (2002)
Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo
D. Brantley (2002)
Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis
D. Hanahan (1996)
Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.
J. Holash (1999)
Structure and function of VEGF/VEGF-receptor system involved in angiogenesis.
M. Shibuya (2001)
RAG-1-deficient mice have no mature B and T lymphocytes
P. Mombaerts (1992)
Can tumor angiogenesis be inhibited without resistance?
K. Miller (2005)
Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans.
A. Sawano (2001)
Effect of p53 Status on Tumor Response to Antiangiogenic Therapy
J. Yu (2002)
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.
G. Klement (2000)
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.
S. Pennacchietti (2003)
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.
G. Bergers (2003)
Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic β cells
T. Adams (1987)
Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor.
M. Dougher-Vermazen (1994)
Molecular pathways regulating mobilization of marrow-derived stem cells for tissue revascularization.
S. Rabbany (2003)
Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment
K. Hattori (2002)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
H. Hurwitz (2004)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
J. Yang (2003)
Immune Enhancement of Skin Carcinogenesis by CD4+ T Cells
D. Daniel (2003)
Effects of angiogenesis inhibitors on multistage carcinogenesis in mice.
G. Bergers (1999)
Angiogenesis inhibitors: motivators of metastasis?
P. Steeg (2003)
Regulation of angiogenesis by hypoxia: role of the HIF system
C. Pugh (2003)
VEGF receptor‐2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis
T. Matsumoto (2005)
Antiangiogenic therapy of transgenic mice impairs de novo tumor growth.
S. Parangi (1996)
This paper is referenced by
Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor
T. Nakagawa (2014)
Anti-angiogenic therapy for cancer and the mechanisms of tumor resistance
Gabriela Jiménez-Valerio (2013)
Signalling Pathways in Cancer-VEGF
K. Badawi (2016)
Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
F. Kuhnert (2015)
Genetically engineered fusion proteins for treatment of cancer.
U. Weidle (2012)
HGF-induced capillary morphogenesis of endothelial cells is regulated by Src.
S. Kanda (2006)
The Pharmacological Effect of Two Antibody Drugs for the Treatment of Tumor Metastasis
K. Kashima (2016)
HGF expression induced by HIF‐1α promote the proliferation and tube formation of endothelial progenitor cells
F. Yu (2015)
Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas
N. Cortes-Santiago (2016)
Tumor resistance to anti-VEGF therapy through up-regulation of VEGF-C expression.
D. Li (2014)
Targeting multiple angiogenic pathways simultaneously: experience with nintedanib in non-small-cell lung cancer.
Greg A Durm (2014)
Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond.
K. Mittal (2014)
The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer.
Rindert Missiaen (2018)
Targeting angiogenesis in advanced cervical cancer
R. Eskander (2014)
Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate.
J. Angulo (2011)
Endothelial CXCR7 Regulates Breast Cancer Metastasis
Amanda C. Stacer (2016)
Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels
Christian Fischer (2007)
7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
R. Frey (2008)
Reduction of brain metastases in plasminogen activator inhibitor-1-deficient mice with transgenic ocular tumors.
C. Maillard (2008)
Pathways mediating VEGF-independent tumor angiogenesis.
N. Ferrara (2010)
Biologic and Systemic Therapies for the Treatment of Hepatocellular Carcinoma
Richard S. Finn (2013)
VEGF and Notch in tip and stalk cell selection.
Raquel Blanco (2013)
Membrane-type matrix metalloproteinases in pericellular proteolysis and melanoma cell invasion
Olga Tatti (2013)
Advances in Lung Cancer and Treatment Research
Xiaofei Wang (2013)
Overcoming Resistance to Targeted Therapies: The Next Challenge in Pancreatic Neuroendocrine Tumors (PNETs) Treatment
Annemilaï Tijeras-Raballand (2014)
Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy.
R. Ronca (2015)
R. Kerbel (2008)
Role of IL 13 RA 2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
N. Shibasaki (2018)
Explorer Stimulation of Tumor Relapse After Chemotherapy by Perivascular , Alternatively Activated Macrophages
Russell Hughes (2015)
A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients
W. Ma (2019)
MRI assessment of hemodynamic effects of angiopoietin-2 overexpression in a brain tumor model.
S. Valable (2009)
Targeting angiogenesis in cancer therapy.
E. Ichihara (2011)See more